298 related articles for article (PubMed ID: 33313998)
41. Atopic dermatitis: an overview.
Berke R; Singh A; Guralnick M
Am Fam Physician; 2012 Jul; 86(1):35-42. PubMed ID: 22962911
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.
Ashcroft DM; Dimmock P; Garside R; Stein K; Williams HC
BMJ; 2005 Mar; 330(7490):516. PubMed ID: 15731121
[TBL] [Abstract][Full Text] [Related]
43. Position statement: topical calcineurin inhibitors in atopic dermatitis.
Remitz A; De Pità O; Mota A; Serra-Baldrich E; Vakirlis E; Kapp A
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2074-2082. PubMed ID: 30288799
[TBL] [Abstract][Full Text] [Related]
44. Treatment-resistant atopic dermatitis: challenges and solutions.
Johnson BB; Franco AI; Beck LA; Prezzano JC
Clin Cosmet Investig Dermatol; 2019; 12():181-192. PubMed ID: 30962700
[TBL] [Abstract][Full Text] [Related]
45. Use of Dexpanthenol for Atopic Dermatitis-Benefits and Recommendations Based on Current Evidence.
Cho YS; Kim HO; Woo SM; Lee DH
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887707
[TBL] [Abstract][Full Text] [Related]
46. Management of atopic dermatitis by pediatricians: A French national survey-based study.
Héron D; Nosbaum A; Braun C
Arch Pediatr; 2023 Apr; 30(3):136-141. PubMed ID: 36804357
[TBL] [Abstract][Full Text] [Related]
47. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients.
Hanifin J; Gupta AK; Rajagopalan R
Br J Dermatol; 2002 Sep; 147(3):528-37. PubMed ID: 12207596
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis.
Sigurgeirsson B; Ho V; Ferrándiz C; Andriano K; Grinienko A; Jimenez P;
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1290-301. PubMed ID: 18624866
[TBL] [Abstract][Full Text] [Related]
49. Treatment options for moderate to severe atopic dermatitis.
Wallace DV
Allergy Asthma Proc; 2022 Nov; 43(6):474-493. PubMed ID: 36335413
[No Abstract] [Full Text] [Related]
50. Prevention of Flares in Children with Atopic Dermatitis with Regular Use of an Emollient Containing Glycerol and Paraffin: A Randomized Controlled Study.
Tiplica GS; Kaszuba A; Malinauskienė L; Konno P; Boralevi F; Garrigue E; Saint-Aroman M; Delarue A
Pediatr Dermatol; 2017 May; 34(3):282-289. PubMed ID: 28271540
[TBL] [Abstract][Full Text] [Related]
51. A starch, glycyrretinic, zinc oxide and bisabolol based cream in the treatment of chronic mild-to-moderate atopic dermatitis in children: a three-center, assessor blinded trial.
Licari A; Ruffinazzi G; DE Filippo M; Castagnoli R; Marseglia A; Agostinis F; Puviani M; Milani M; Marseglia GL
Minerva Pediatr; 2017 Dec; 69(6):470-475. PubMed ID: 29181960
[TBL] [Abstract][Full Text] [Related]
52. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study.
Meurer M; Fölster-Holst R; Wozel G; Weidinger G; Jünger M; Bräutigam M;
Dermatology; 2002; 205(3):271-7. PubMed ID: 12399676
[TBL] [Abstract][Full Text] [Related]
53. Spotlight on topical pimecrolimus in pediatric atopic dermatitis.
Yang LP; Curran MP
Am J Clin Dermatol; 2010; 11(4):295-8. PubMed ID: 20509720
[TBL] [Abstract][Full Text] [Related]
54. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Hultsch T; Kapp A; Spergel J
Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
[TBL] [Abstract][Full Text] [Related]
55. Pimecrolimus in dermatology: atopic dermatitis and beyond.
Gisondi P; Ellis CN; Girolomoni G
Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
[TBL] [Abstract][Full Text] [Related]
56. Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues.
Czarnecka-Operacz M; Jenerowicz D
J Dtsch Dermatol Ges; 2012 Mar; 10(3):167-72. PubMed ID: 21974750
[TBL] [Abstract][Full Text] [Related]
57. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
Werfel T
J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820
[TBL] [Abstract][Full Text] [Related]
58. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
[TBL] [Abstract][Full Text] [Related]
59. Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis.
Guttman-Yassky E; Ungar B; Malik K; Dickstein D; Suprun M; Estrada YD; Xu H; Peng X; Oliva M; Todd D; Labuda T; Suarez-Farinas M; Bissonnette R
J Allergy Clin Immunol; 2017 Oct; 140(4):1032-1042.e13. PubMed ID: 28238742
[TBL] [Abstract][Full Text] [Related]
60. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
Hoeger PH; Lee KH; Jautova J; Wohlrab J; Guettner A; Mizutani G; Hultsch T
Br J Dermatol; 2009 Feb; 160(2):415-22. PubMed ID: 19067708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
